Withdrawals due to adverse events · adults with sickle cell disease in a vaso‐occlusive crisis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · adults with sickle cell disease in a vaso‐occlusive crisis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with collagenous colitis
Mesalamine showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with collagenous colitis
It is very uncertain whether budesonide changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with collagenous colitis
Boswellia serrata extract showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with collagenous colitis
Budesonide showed no clear difference in withdrawals due to adverse events compared with mesalazine (low certainty).
1 finding from 1 review
Adverse events (number of events) · people with acute HBV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: avascular necrosis · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether steroids changes adverse events: avascular necrosis compared with no specific treatment (very low certainty).
1 finding from 1 review
Adverse events ‐ treatment failure · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in adverse events ‐ treatment failure compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
Adverse events: serious infections · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor showed no clear difference in adverse events: serious infections compared with IV cyclophosphamide (moderate certainty).
1 finding from 1 review
Adverse events: death (all causes) · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in adverse events: death (all causes) compared with prednisone or placebo (low certainty).
1 finding from 1 review
Primary outcome 3: Adverse events · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (nausea, dizziness) · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Acute kidney injury · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in adverse events: acute kidney injury compared with oral steroids alone (low certainty).
1 finding from 1 review
Acute kidney injury · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in adverse events: acute kidney injury compared with oral steroids alone (low certainty).
1 finding from 1 review
Major adverse outcome: total events · adults with fractures of the patella
It is very uncertain whether percutaneous patellar osteosynthesis changes major adverse outcome: total events compared with open surgery (very low certainty).
1 finding from 1 review
Adverse events ‐ treatment emergent · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ treatment emergent · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (1.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
1 finding from 1 review
Number of women with adverse events · postpartum breastfeeding women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women with adverse events · postpartum breastfeeding women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found